242 related articles for article (PubMed ID: 24817210)
1. Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.
Tang W; Huang Q; Yao YY; Wang Y; Wu YL; Wang ZY
J Neural Transm (Vienna); 2014 Dec; 121(12):1541-53. PubMed ID: 24817210
[TBL] [Abstract][Full Text] [Related]
2. Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
Tang W; Huang Q; Wang Y; Wang ZY; Yao YY
J Neurol Sci; 2014 Oct; 345(1-2):26-36. PubMed ID: 25086857
[TBL] [Abstract][Full Text] [Related]
3. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
4. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
6. Changes of cerebrospinal fluid Aβ
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Nov; 38(11):1953-1961. PubMed ID: 28808876
[TBL] [Abstract][Full Text] [Related]
7. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
9. Blood Neurofilament Light Chain in Different Types of Dementia.
Gu L; Shu H; Wang Y; Wang P
Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
[TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
13. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
[TBL] [Abstract][Full Text] [Related]
14. CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.
Hansson O; Santillo AF; Meeter LH; Nilsson K; Landqvist Waldö M; Nilsson C; Blennow K; van Swieten JC; Janelidze S
Ann Clin Transl Neurol; 2019 May; 6(5):863-872. PubMed ID: 31139684
[TBL] [Abstract][Full Text] [Related]
15. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
[TBL] [Abstract][Full Text] [Related]
16. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
17. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature.
Diniz BS; Pinto Júnior JA; Forlenza OV
World J Biol Psychiatry; 2008; 9(3):172-82. PubMed ID: 17886169
[TBL] [Abstract][Full Text] [Related]
18. Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.
Boström G; Freyhult E; Virhammar J; Alcolea D; Tumani H; Otto M; Brundin RM; Kilander L; Löwenmark M; Giedraitis V; Lleó A; von Arnim CAF; Kultima K; Ingelsson M
J Alzheimers Dis; 2021; 81(2):629-640. PubMed ID: 33814444
[TBL] [Abstract][Full Text] [Related]
19. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
20. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]